BKGI-R Stock Overview

Provides clinical and genomics services in Thailand. More details

BKGI-R fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	5/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 72.4% below our estimate of its fair value

Earnings are forecast to grow 23.16% per year

Revenue grew by 13.8% over the past year

Risk Analysis

High level of non-cash earnings

Less than 3 years of financial data is available

Does not have a meaningful market cap (THB1B)

Volatile share price over the past 3 months compared to the TH market

My Notes

Capture your thoughts, links and company narrative

Bangkok Genomics Innovation Public Company Limited Competitors

Dental Corporation

SET:D

฿1.0b

Genesis Fertility Center

SET:GFC

฿1.5b

Inspire IVF

SET:IVF

฿704.0m

KT Medical Service

SET:KTMS

฿612.0m

Price History & Performance

Summary of share price highs, lows and changes for Bangkok Genomics Innovation
Historical stock prices
Current Share Price	฿1.97
52 Week High	฿5.65
52 Week Low	฿1.67
Beta	0
1 Month Change	-8.80%
3 Month Change	-32.07%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-55.23%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	BKGI-R	TH Healthcare	TH Market
7D	-11.3%	-3.5%	-4.7%
1Y	n/a	-15.5%	-3.4%

Return vs Industry: Insufficient data to determine how BKGI-R performed against the TH Healthcare industry.

Return vs Market: Insufficient data to determine how BKGI-R performed against the TH Market.

Price Volatility

Is BKGI-R's price volatile compared to industry and market?
BKGI-R volatility
BKGI-R Average Weekly Movement	7.2%
Healthcare Industry Average Movement	4.1%
Market Average Movement	4.3%
10% most volatile stocks in TH Market	8.9%
10% least volatile stocks in TH Market	2.1%

Stable Share Price: BKGI-R's share price has been volatile over the past 3 months compared to the TH market.

Volatility Over Time: BKGI-R's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of TH stocks.

About the Company

Founded	Employees	CEO	Website
2017	n/a	n/a	www.bangkokgenomics.com

Bangkok Genomics Innovation Public Company Limited provides clinical and genomics services in Thailand. The company offers non-invasive prenatal testing which includes screening for fetal chromosomal abnormalities under the NIFTY brand; and genetic disease carrier screening testing services, such as screening before embryo implantation, carriers of genetic disease, and detection of gene abnormalities associated with thalassemia anemia under the VISTA brand. It also provides real time-PCR test for COVID-19, antigen testing of the COVID-19, SARS-CoV-2 serology testing, SARS-CoV-2 neutralizing antibody testing, and real time-PCR for monkeypox virus testing, as well as HPV DNA test; colon cancer testing under the COLOTECH brand; and individual genetic testing services under the DNALL brand.

Bangkok Genomics Innovation Public Company Limited Fundamentals Summary

How do Bangkok Genomics Innovation's earnings and revenue compare to its market cap?
BKGI-R fundamental statistics
Market cap	฿1.18b
Earnings (TTM)	฿44.49m
Revenue (TTM)	฿296.39m

26.6x

P/E Ratio

4.0x

P/S Ratio

Is BKGI-R overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BKGI-R income statement (TTM)
Revenue	฿296.39m
Cost of Revenue	฿172.08m
Gross Profit	฿124.31m
Other Expenses	฿79.82m
Earnings	฿44.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.074
Gross Margin	41.94%
Net Profit Margin	15.01%
Debt/Equity Ratio	0%

How did BKGI-R perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/21 22:32
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bangkok Genomics Innovation Public Company Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Watcharain Jongyanyong	Globlex Securities Co. Ltd.
Mintra Rattayapas	Krungsri Securities Public Company Limited